Affordable Access

Access to the full text

Drug compliance in patients with systemic scleroderma

Authors
  • Hromadkova, Lucie1
  • Soukup, Tomas2
  • Cermakova, Eva3
  • Vlcek, Jiri1
  • 1 Charles University in Prague, Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Heyrovskeho 1203, Hradec Kralove, 500 05, Czech Republic , Hradec Kralove (Czechia)
  • 2 Charles University in Prague, 2nd Department of Internal Medicine, University Hospital and Faculty of Medicine, Sokolska 581, Hradec Kralove, 500 05, Czech Republic , Hradec Kralove (Czechia)
  • 3 Charles University in Prague, Computer Technology Centre, Faculty of Medicine, Šimkova 870, Hradec Kralove, 500 38, Czech Republic , Hradec Kralove (Czechia)
Type
Published Article
Journal
Clinical Rheumatology
Publisher
Springer-Verlag
Publication Date
Aug 09, 2012
Volume
31
Issue
11
Pages
1577–1583
Identifiers
DOI: 10.1007/s10067-012-2050-0
Source
Springer Nature
Keywords
License
Yellow

Abstract

Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (≥80 %). No relationships between various demographic and clinical characteristics and CQR score expressed as continuous or dichotomous variables were found. This study represents the first evaluation of drug compliance in patients with systemic scleroderma. Many noncompliant patients were identified, but no common risk factors for noncompliance were discovered. The reasons for noncompliance seem to depend on the personal features of the patients.

Report this publication

Statistics

Seen <100 times